| A Study to Test the Effects of Tolterodine Tartrate in Patients With Overactive Bladder (0000-107) (NCT00768521) | Merck Sharp & Dohme LLC | 2008-09-03 |
| Feasibility of "At-home" Titration of Solifenacin (NCT00759577) | NYU Langone Health | 2008-09-01 |
| Study of Urgent PC Versus Sham Effectiveness in Treatment of Overactive Bladder Symptoms (NCT00771264) | Uroplasty, Inc | 2008-09-01 |
| A Safety Extension Study of DR-OXY-301 (NCT00782769) | Duramed Research | 2008-09-01 |
| A Clinical Study to Determine the Effect of YM178 on the Pharmacokinetics of Warfarin in Healthy Subjects (NCT00856570) | Astellas Pharma Inc | 2008-09-01 |
| Study In Patients With Overactive Bladder Treated With Toviaz® After Failure Of Previous Therapy (NCT00691093) | Pfizer | 2008-07-01 |
| Pilot Study: Is Overactive Bladder Caused by Subacute Urinary Tract Infections? (NCT00714792) | University of Rochester | 2008-06-01 |
| A Clinical Trial to Evaluate the Efficacy and Safety of DR-3001 in Women With Overactive Bladder (NCT00685113) | Duramed Research | 2008-05-01 |
| Comparison of Caffeine Reduction and Anticholinergic Medications for Treatment of Overactive Bladder (NCT00780832) | IWK Health Centre | 2008-05-01 |
| Uro-NIRS Clinical Study (NCT00706407) | Weill Medical College of Cornell University | 2008-04-01 |
| Over Active Bladder Instillation Study - Botox (NCT00667095) | Mayo Clinic | 2008-04-01 |
| Caffeine Reduction and Overactive Bladder Symptoms (NCT00754260) | University of New Mexico | 2008-03-01 |
| Over Active Bladder Patients Having Sling Surgery (NCT00852696) | Cleveland Clinic Florida | 2008-02-01 |
| Long Term Study To Evaluate the Safety, Tolerability and Efficacy of Fesoterodine for Overactive Bladder. (NCT00658684) | Pfizer | 2008-02-01 |
| Autologous Neo-Bladder Construct in Non-Neurogenic Overactive Bladder and Urge Predominant Incontinence (NCT00594139) | Tengion | 2008-01-01 |
| Combined Anticholinergic Medication and Sacral Neuromodulation to Treat Refractory Overactive Bladder (NCT01047046) | University of California, Irvine | 2008-01-01 |
| Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Neurogenic Overactive Bladder (NCT00575016) | Allergan | 2007-12-01 |
| Dose-Finding Study To Evaluate The Efficacy, Tolerability And Safety Of Fesoterodine In Comparison To Placebo For Overactive Bladder. (NCT00561951) | Pfizer | 2007-11-01 |
| SSR240600C Treatment in Women With Overactive Bladder (NCT00564226) | Sanofi | 2007-11-01 |
| InSite for Over Active Bladder (NCT00547378) | MedtronicNeuro | 2007-10-01 |
| Study to Evaluate the Clinical Efficacy and Safety of Tamsulosin Alone or in Combination With Solifenacin for the Treatment in Men With Lower Urinary Tract Symptoms Including Overactive Bladder Symptoms (NCT02715024) | Astellas Pharma Taiwan, Inc. | 2007-09-01 |
| Posterior Tibial Nerve Stimulation vs. Sham (NCT00534521) | Corewell Health East | 2007-09-01 |
| The Study To Test The Effect of Standardization Of Fluid Intake In Female Patients With Overactive Bladder (NCT00553657) | GlaxoSmithKline | 2007-08-01 |
| Long-term Safety and Efficacy of Imidafenacin in Patients With Overactive Bladder (NCT00512785) | Ono Pharmaceutical Co., Ltd. | 2007-08-01 |
| Fesoterodine Flexible Dose Study (NCT00536484) | Pfizer | 2007-08-01 |
| A Study To Assess If 10 mg Vardenafil (BAY38-9456) Taken Twice Daily For 6 Weeks Has An Effect On Bladder Function (NCT00478881) | Bayer | 2007-08-01 |
| FREEDOM - First Real-Life Evaluation of Enablex Done in ZA Overactive Bladder Patients During a 3 Months Period (NCT00921245) | Bayer | 2007-06-01 |
| A Study To Test The Interaction of Two Medications for Treatment of Overactive Bladder (NCT00501267) | GlaxoSmithKline | 2007-06-01 |
| Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Neurogenic Overactive Bladder (NCT00439140) | Allergan | 2007-06-01 |
| Evaluation of the Link Between Bladder Sensation and Changes in Skin Electrical Conductance and Heart Rate. (NCT00481728) | Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | 2007-06-01 |
| Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Neurogenic Overactive Bladder (NCT00461292) | Allergan | 2007-05-01 |
| Detrol Long Acting (LA) vs Estrace Vaginal Cream for the Treatment of Overactive Bladder Symptoms (NCT00465894) | University of Alabama at Birmingham | 2007-04-01 |
| Safety Study of hMaxi-K Gene Transfer to Treat Overactive Bladder and Detrusor Overactivity (NCT00495053) | Urovant Sciences GmbH | 2007-04-01 |
| Urinary Cytokines in Patients With Overactive Bladder (OAB) (NCT00868621) | The Cleveland Clinic | 2007-03-01 |
| Microorganism in Overactive Bladder Patients (NCT00883818) | Samsung Medical Center | 2007-01-01 |
| A Clinical Trial To Assess Fesoterodine On Treatment Satisfaction And Symptom Improvement In Overactive Bladder Patients (NCT00425100) | Pfizer | 2007-01-01 |
| A Two-Part Study to Determine: Best Medication Formulation and Food Effect (NCT00427596) | GlaxoSmithKline | 2007-01-01 |
| This is a Prospective, Randomized, Double-Blind Study Comparing Intravesical Injection of Botox® to Placebo. (NCT00479596) | Urological Sciences Research Foundation | 2007-01-01 |
| Efficacy and Safety of Selective Serotonin Reuptake Inhibitor (SSRI) in Overactive Bladder Patients (NCT00902421) | Samsung Medical Center | 2007-01-01 |
| Tolterodine Drug Use Investigation.(Post Marketing Commitment Plan) (NCT01488578) | Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | 2006-12-01 |
| Study to Compare the Safety and Efficacy of Solifenacin With Oxybutynin for the Treatment of Overactive Bladder (VECTOR) (NCT00431041) | Astellas Pharma Inc | 2006-12-01 |
| Safety and Applicability Study of a Novel Heat Flow Sensor Unit for Measuring Urinary Bladder Capacity (NCT00437528) | Rambam Health Care Campus | 2006-11-01 |
| Changes in Inflammatory and Contractile Protein Expression in Patients With Painful Bladder Syndrome/IC. (NCT00775281) | Insel Gruppe AG, University Hospital Bern | 2006-10-01 |
| Behavioral Modification and Vesicare Versus Vesicare Alone for Urge Incontinence in Patients With Overactive Bladder (NCT00821184) | Lahey Clinic | 2006-09-01 |
| Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Neurogenic Overactive Bladder (NCT00311376) | Allergan | 2006-08-01 |
| Exploring Predictors of Symptoms Relapse After Discontinuation of Treatment in Overactive Bladder (OAB) Patients (NCT00730535) | KYU-SUNG LEE | 2006-08-01 |
| Overactive Bladder Innovative Therapy Trial (OrBIT) (NCT00448175) | Uroplasty, Inc | 2006-06-01 |
| A Comparison of a New Drug to Treat Overactive Bladder vs. Placebo (NCT00350636) | Watson Pharmaceuticals | 2006-06-01 |
| A Study of Solifenacin With Bladder Training Versus Solifenacin Alone in Patients With Overactive Bladder (SOLAR) (NCT00337558) | Astellas Pharma Inc | 2006-05-01 |
| Botulin-A Toxin Instillations and Overactive Bladder (NCT00583219) | Mayo Clinic | 2006-03-01 |
| Local Anesthetic Treatments for Overactive Bladder (NCT00427648) | Frank Tu | 2006-03-01 |
| Safety and Efficacy of MK0594 to Treat Overactive Bladder (0594-003) (NCT00290563) | Vyne Therapeutics Inc. | 2006-02-21 |
| Assessing the OAB-8 Questionnaire as a Tool to Measure Treatment Outcome (NCT00313924) | Rambam Health Care Campus | 2006-02-01 |
| Safety And Efficacy Of Solifenacin In Men With Overactive Bladder (OAB) And Detrusor Underactivity (NCT00441428) | University of L'Aquila | 2006-02-01 |
| Surface Nerve Stimulation Treatment for OAB in Children (NCT00282490) | University of Aarhus | 2006-02-01 |
| Effects Of GW679769 On Bladder Nerve Function And Symptoms Of Overactive Bladder In Spinal Cord Injury Patients (NCT00332319) | GlaxoSmithKline | 2006-01-01 |
| Investigation of Tolterodine, Pregabalin and a Tolterodine - Pregabalin Combination for the Treatment of Overactive Bladder (NCT00746681) | Pfizer | 2005-12-01 |
| Efficacy and Safety of Botulinum Toxin A for the Treatment of Refractory Overactive Bladder. (NCT00231491) | Assistance Publique - Hôpitaux de Paris | 2005-11-01 |
| A Research Study for Patients With Overactive Bladder (NCT00168454) | Allergan | 2005-07-01 |
| MILADY: A Randomized, Placebo-controlled Safety and Efficacy Trial of SSR240600C in Treatment of Overactive Bladder or Urge Urinary Incontinence. (NCT00174798) | Sanofi | 2005-05-01 |
| Efficacy, Safety, and Tolerability of Darifenacin in Patients Aged > 65 Years With Overactive Bladder (NCT00171184) | Novartis | 2005-04-01 |
| Programmable Timer in the Bladder Rehabilitation Treatment of OAB (NCT00238680) | University of Aarhus | 2005-03-01 |
| Post Marketing Surveillance Study on Emselex After Launch in Germany (NCT00786448) | Bayer | 2005-01-01 |
| Urinary Urgency Outcomes Following Propiverine Treatment for an Overactive Bladder (NCT00903045) | Samsung Medical Center | 2005-01-01 |
| Behavioral Treatment of Overactive Bladder in Men (NCT01187498) | US Department of Veterans Affairs | 2005-01-01 |
| Diagnosis of Bladder Pain Syndrome / Interstitial Cystitis (NCT03023241) | Cantonal Hospital, Frauenfeld | 2004-12-01 |
| Dose-Escalating Study of Propiverine Hydrochloride in Children Suffering From Overactive Bladder (NCT00795925) | APOGEPHA Arzneimittel GmbH | 2004-10-01 |
| Propiverine in Children Suffering From Non-Neurogenic Overactive Bladder and Urinary Incontinence (NCT00603343) | APOGEPHA Arzneimittel GmbH | 2004-06-01 |
| Transdermal (TDS) Oxybutynin (Oxytrol(r)) in Overactive Bladder (NCT00224146) | Watson Pharmaceuticals | 2004-05-01 |
| An Implantable Microstimulator for the Chronic Treatment of Urinary Urgency-Frequency Syndrome (NCT00131573) | Boston Scientific Corporation | 2004-05-01 |
| Topical Oestrogens and Antimuscarinics In The Treatment Of Detrusor Overactivity (NCT00648310) | Università degli Studi dell'Insubria | 2004-01-01 |
| Controlled Study of ONO-8025 (KRP-197) in Patients With Overactive Bladder in Japan (NCT00212732) | Ono Pharmaceutical Co., Ltd. | 2003-10-01 |
| Trial to Investigate the Efficacy, Tolerability and Safety of Fesoterodine Sustained Release in Subjects With Overactive Bladder Syndrome (NCT00138723) | Pfizer | 2003-10-01 |
| Two Phase Extension Trial of SP668 to Investigate the Safety and Tolerability of Sustained Release Fesoterodine in Subjects With Overactive Bladder: a Double-Blind Phase Followed by an Open-Label Extension Phase (NCT00220389) | Pfizer | 2003-06-01 |
| Screening Method in Sacral Neuromodulation (NCT01130415) | Maastricht University Medical Center | 2002-05-01 |
| Controlled Study of ONO-8025 (KRP-197) in Patients With Overactive Bladder in Japan (NCT00212706) | Ono Pharmaceutical Co., Ltd. | 2001-10-01 |
| A Study of Solifenacin Succinate Compared to Tolterodine in Patients With Overactive Bladder (NCT00189800) | Astellas Pharma Inc | |
| Botulinum-A Toxin Injection for Detrusor Hyperreflexia in Spinal Cord Injury: A Non-Surgical Approach. (NCT00262496) | US Department of Veterans Affairs | |
| A Confirmatory Study of KUC-7483 in Patients With Overactive Bladder (NCT01004315) | Kissei Pharmaceutical Co., Ltd. | |
| A Study of YM178 in Patients With Symptomatic Overactive Bladder (DRAGON) (NCT00337090) | Astellas Pharma Inc | |